|
ACD
|
Australian
Cancer Database
|
|
Act
|
National
Health Act 1953
|
|
AIHW
|
Australian
Institute of Health and Welfare
|
|
ALK
|
anaplastic
lymphoma kinase
|
|
ALLG
|
Australasian
Leukaemia and Lymphoma Group
|
|
AMWG
|
Access
to Medicines Working Group
|
|
ANZCHOG
|
Australian
New Zealand Children's Haematology/Oncology Group
|
|
ARTG
|
Australian
Register of Therapeutic Goods
|
|
AusPAR
|
Australian Public
Assessment Report
|
|
AYAs
|
adolescents and young
adults
|
|
BCNA
|
Breast
Cancer Network Australia
|
|
CADTH
|
Canadian
Agency for Drug Technologies and Health
|
|
CAV
|
Cancer
Action Victoria
|
|
CBCF
|
Cure
Brain Cancer Foundation
|
|
CCA/COSA
|
Cancer
Council Australia/Clinical Oncology Society of Australia
|
|
CDA
|
Cancer
Drugs Alliance
|
|
CDF
|
Cancer
Drugs Fund
|
|
CDR
|
Common
Drug Review
|
|
CLL
|
Chronic
Lymphocytic Leukaemia
|
|
committee
|
Senate
Community Affairs Reference Committee
|
|
Council
|
United
Kingdom Citizen's Council
|
|
CVA
|
Cancer
Voices Australia
|
|
DAE
|
Deloitte
Access Economics
|
|
DOH
|
Department
of Health
|
|
EFC
|
Efficient
Funding of Chemotherapy
|
|
EMA
|
European
Medicines Agency
|
|
F1
|
Formulary
1 medicines
|
|
F2
|
Formulary
2 medicines
|
|
FDA
|
Food
and Drug Administration
|
|
Guidelines
|
Pharmaceutical
Benefits Advisory Committee Guidelines
|
|
HSANZ
|
Haematology
Society of Australia and New Zealand
|
|
HTA
|
Health
Technology Assessment
|
|
HSDP
|
Highly
Specialised Drugs Program
|
|
IARC
|
International
Agency for Research on Cancer
|
|
ICER
|
Incremental
Cost Effectiveness Ratio
|
|
IPU
|
Individual
Patient Use
|
|
Janssen
|
Janssen-Cilag
Pty Ltd
|
|
LFA
|
Leukaemia
Foundation of Australia
|
|
Lilly
|
Eli
Lilly Australia
|
|
LSDP
|
Life
Saving Drugs Programme
|
|
MA
|
Medicines
Australia
|
|
MAP
|
Managed
Access Programme
|
|
MBS
|
Medical
Benefits Schedule
|
|
MES
|
Managed
Entry Scheme
|
|
Minister
|
Minister
for Health
|
|
MOGA
|
Medical
Oncology Group of Australia
|
|
MSAC
|
Medical
Services Advisory Committee
|
|
MSD
|
Merck
Sharp and Dohme
|
|
NCR
|
national
chemotherapy registry
|
|
NICE
|
National
Institute for Health and Care Excellence
|
|
NHPA
|
National
Health Priority Areas
|
|
NHS
|
National
Health Service
|
|
NMP
|
National
Medicines Policy
|
|
NN
|
Novo
Nordisk
|
|
Novartis
|
Novartis
Oncology Australia New Zealand
|
|
OCA
|
Ovarian
Cancer Australia
|
|
OS
|
overall
survival
|
|
Panel
|
Expert
Panel, Review of Medicines and Medical Devices
|
|
PAG
|
Provincial
Advisory Group
|
|
PATS
|
Patient
Assisted Travel Schemes
|
|
PBAC
|
Pharmaceutical
Benefits Advisory Committee
|
|
PBS
|
Pharmaceutical
Benefits Scheme
|
|
pCODR
|
pan-Canadian
Oncology Drug Review
|
|
PCPA
|
Private
Cancer Physicians of Australia
|
|
pERC
|
pCODR
Expert Review Committee
|
|
PFS
|
Progression
Free Survival
|
|
Price
Agreement
|
An
agreement made under section 85AD of the National Health Act 1953
|
|
RCA
|
Rare
Cancers Australia
|
|
SAS
|
Special
Access Scheme
|
|
SHPA
|
Society
of Hospital Pharmacists of Australia
|
|
SIBs
|
social
impact bonds
|
|
TGA
|
Therapeutic
Goods Administration
|
|
UK
|
United
Kingdom
|
|
US
|
United
States
|
|
WISH
|
World
Innovation Summit for Health
|
|
WM
|
Waldenstrom's
Macroglobulinemia
|